Your browser doesn't support javascript.
loading
Elecsys® and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable?
Stepan, Holger; Hund, Martin; Dilba, Peter; Sillman, Johanna; Schlembach, Dietmar.
Afiliación
  • Stepan H; Department of Obstetrics, University of Leipzig, Liebigstr. 20a, 04103, Leipzig, Germany.
  • Hund M; Roche Diagnostics International Ltd, Rotkreuz, Switzerland.
  • Dilba P; Roche Diagnostics GmbH, Penzberg, Germany.
  • Sillman J; Roche Diagnostics International Ltd, Rotkreuz, Switzerland.
  • Schlembach D; Vivantes Network of Health, Clinicum Neukoelln, Clinic of Obstetrics, Berlin, Germany.
Clin Chem Lab Med ; 57(9): 1339-1348, 2019 08 27.
Article en En | MEDLINE | ID: mdl-31323000
ABSTRACT
Background For pregnant women with suspected preeclampsia, the soluble fms-like tyrosine-kinase 1 (sFlt-1)/placental growth factor (PlGF) ratio is a biomarker to aid diagnosis. We performed method comparisons between Elecsys® and Kryptor sFlt-1 and PlGF immunoassays and assessed the diagnostic performance for preeclampsia. Methods Serum samples from a case-control study involving 113 pregnant women with preeclampsia/elevated liver enzymes and low platelet count (HELLP) and 270 controls were analyzed. sFlt-1 and PlGF were measured using Roche Elecsys® and BRAHMS Kryptor sFlt-1/PlGF immunoassays. The sFlt-1/PlGF ratios were calculated, and Passing-Bablok regression/Bland-Altman plots were performed. Gestation-specific cut-offs, ≤33 and ≥85/≥110, were assessed. Results Mean (±2 standard deviation [SD]) differences between the Elecsys® and Kryptor values were sFlt-1, 173.13 pg/mL (6237.66, -5891.40); PlGF, -102.71 pg/mL (186.06, -391.48); and sFlt-1/PlGF, 151.74 (1085.11, -781.63). The Elecsys® and Kryptor immunoassays showed high correlation Pearson's correlation coefficients were 0.913 (sFlt-1) and 0.945 (PlGF). Slopes were 1.06 (sFlt-1) and 0.79 (PlGF), resulting in ~20% lower values for Kryptor PlGF. Sensitivities and specificities using the sFlt-1/PlGF ≥85 cut-off for early-onset preeclampsia (20 + 0 to 33 + 6 weeks) were 88.1%/100.0% (Elecsys®) and 90.5%/96.2% (Kryptor), respectively, and using the ≥110 cut-off for late-onset preeclampsia (≥34 + 0 weeks) were 51.3%/96.5% (Elecsys®) and 78.9%/90.1% (Kryptor), respectively. Using Elecsys® and Kryptor sFlt-1/PlGF, 0% and 3.8% of women, respectively, were falsely ruled-in for early-onset, and 3.5% and 9.9%, respectively, for late-onset preeclampsia. Conclusions Despite high correlation between the Elecsys® and Kryptor immunoassays, we observed significant differences between sFlt-1/PlGF and PlGF results. Therefore, sFlt-1/PlGF cut-offs validated for Elecsys® immunoassays are not transferable to Kryptor immunoassays.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Preeclampsia / Receptor 1 de Factores de Crecimiento Endotelial Vascular / Factor de Crecimiento Placentario Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Clin Chem Lab Med Asunto de la revista: QUIMICA CLINICA / TECNICAS E PROCEDIMENTOS DE LABORATORIO Año: 2019 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Preeclampsia / Receptor 1 de Factores de Crecimiento Endotelial Vascular / Factor de Crecimiento Placentario Tipo de estudio: Diagnostic_studies / Observational_studies Límite: Adult / Female / Humans / Pregnancy Idioma: En Revista: Clin Chem Lab Med Asunto de la revista: QUIMICA CLINICA / TECNICAS E PROCEDIMENTOS DE LABORATORIO Año: 2019 Tipo del documento: Article País de afiliación: Alemania